"10.1371_journal.pone.0136549","plos one","2015-09-02T00:00:00Z","Michael Roth; Feng Zhao; Jun Zhong; Didier Lardinois; Michael Tamm","Pulmonary Cell Research, Department Biomedicine, University Basel, Basel, Switzerland; Department Internal Medicine, Pneumology, University Hospital Basel, Basel, Switzerland; Department of Respiratory Diseases, Xijing Hospital, 4th Military Medical University, Xian, Peoples Republic of China; Department Thoracic Surgery, University Hospital Basel, Basel, Switzerland","Conceived and designed the experiments: MR MT. Performed the experiments: MR FZ JZ. Analyzed the data: MR FZ MT. Contributed reagents/materials/analysis tools: DL MT. Wrote the paper: MR DL MT.","This study was funded by Novartis Pharma Schweiz AG, CIGE025A, an unrestricted Research grant to MT. Novartis are the makers of Omalizumab. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","09","Michael Roth","MR",5,TRUE,2,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
